Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study

Gynecologic Oncology

Volumn 141, Issue 3, 2016, Pages 559-563

  Köbel, Martin ^a   Atenafu, Eshetu G ^b,c   Rambau, Peter F ^a   Ferguson, Sarah E ^d   Nelson, Gregg S ^a   Ho, T C ^c   Panzarella, Tony ^b,c   McAlpine, Jessica N ^e   Gilks, C Blake ^e   Clarke, Blaise A ^c   Bernardini, Marcus Q ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Endometrial cancer; Endometrioid; ER; Highgrade; Hormone receptor; PR; Prognosis; Serous

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; EXONUCLEASE; POLE EXONUCLEASE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL LABELING; CELL NUCLEUS; COHORT ANALYSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN DOMAIN; TISSUE MICROARRAY; TISSUE SECTION; TUMOR INVASION; BIOSYNTHESIS; CANADA; CLINICAL TRIAL; ENDOMETRIUM TUMOR; EPIDEMIOLOGY; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

CANADA; CARCINOMA, ENDOMETRIOID; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84963636114     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.04.008     Document Type: Article

References (38)

1. Abbotts, R., Thompson, N., Madhusudan, S., DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag. Res. 6 (2014), 77–92.
2. Hamilton, C.A., Cheung, M.K., Osann, K., Chen, L., Teng, N.N., Longacre, T.A., et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer 94 (2006), 642–646.
3. Bokhman, J.V., Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15 (1983), 10–17.
4. Ryan, P., Mulligan, A.M., Aronson, M., Ferguson, S.E., Bapat, B., Semotiuk, K., et al. Comparison of clinical schemas and morphologic features in predicting lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer 118 (2012), 681–688.
5. Clarke, B.A., Cooper, K., Identifying lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv. Anat. Pathol. 19 (2012), 231–238.
6. Mills, A.M., Liou, S., Ford, J.M., Berek, J.S., Pai, R.K., Longacre, T.A., Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am. J. Surg. Pathol. 38 (2014), 1501–1509.
7. Darvishian, F., Hummer, A.J., Thaler, H.T., Bhargava, R., Linkov, I., Asher, M., Soslow, R.A., Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am. J. Surg. Pathol. 28 (2004), 1568–1578.
8. Alkushi, A., Köbel, M., Kalloger, S.E., Gilks, C.B., High-grade endometrial carcinoma: Serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int. J. Gynecol. Pathol. 29 (2010), 343–350.
9. Engelsen, I.B., Akslen, L.A., Salvesen, H.B., Biologic markers in endometrial cancer treatment. APMIS 117 (2009), 693–707.
10. Wik, E., Ræder, M.B., Krakstad, C., Trovik, J., Birkeland, E., Hoivik, E.A., et al. Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin. Cancer Res. 19 (2013), 1094–1105.
11. Trovik, J., Wik, E., Werner, H.M.J., Krakstad, C., Helland, H., Vandenput, I., et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur. J. Cancer 49 (2013), 3431–3441.
12. Huvila, J., Talve, L., Carpén, O., Edqvist, P.-H., Pontén, F., Grénman, S., Auranen, A., Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol. Oncol. 130 (2013), 463–469.
13. Togami, S., Sasajima, Y., Oi, T., Ishikawa, M., Onda, T., Ikeda, S.-I., et al. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci. 103 (2012), 926–932.
14. Altman, A.D., Ferguson, S.E., Atenafu, E.G., Köbel, M., McAlpine, J.N., Panzarella, T., et al. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behaviour of high risk endometrial cancers. Gynecol. Oncol. 139 (2015), 269–274.
15. Hoang, L.N., Han, G., McConechy, M., Lau, S., Chow, C., Gilks, C.B., et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma — diagnostic utility of HNF1B and estrogen receptor. Histopathology 33 (2013), 483–491.
16. Tafe, L.J., Garg, K., Chew, I., Tornos, C., Soslow, R.A., Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod. Pathol. 23 (2010), 781–789.
17. Han, G., Sidhu, D., Duggan, M.A., Arseneau, J., Cesari, M., Clement, P.B., et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod. Pathol. 26 (2013), 1594–1604.
18. Bernardini, M.Q., Gien, L.T., Lau, S., Altman, A.D., Gilks, B., Ferguson, S.E., et al. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol. Oncol. 141 (2016), 148–154.
19. Meng, B., Hoang, L.N., McIntyre, J.B., Duggan, M.A., Nelson, G.S., Lee, C.-H., Köbel, M., POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol. Oncol. 134 (2014), 15–19.
20. Allo, G., Bernardini, M.Q., Wu, R.-C., Shih, I.-M., Kalloger, S., Pollett, A., et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod. Pathol. 27 (2014), 255–261.
21. Talhouk, A., McConechy, M.K., Leung, S., Li-Chang, H.H., Kwon, J.S., Melnyk, N., et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 113 (2015), 299–310.
22. Terry, J., Torlakovic, E.E., Garratt, J., Miller, D., Köbel, M., Cooper, J., et al. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian quality control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 17 (2009), 375–382.
23. Sieh, W., Köbel, M., Longacre, T.A., Bowtell, D.D., Defazio, A., Goodman, M.T., et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 14 (2013), 853–862.
24. Fader, A.N., Starks, D., Gehrig, P.A., Secord, A.A., Frasure, H.E., O'Malley, D.M., et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 115 (2009), 244–248.
25. Pérez, T., Makrestsov, N., Garatt, J., Torlakovic, E., Gilks, C.B., Mallett, S., Modeling Canadian quality control test program for steroid hormone receptors in breast cancer: diagnostic accuracy study. Appl. Immunohistochem. Mol. Morphol., 2015.
26. Guan, H., Semaan, A., Bandyopadhyay, S., Arabi, H., Feng, J., Fathallah, L., et al. Prognosis and reproducibility of new and existing binary grading systems for endometrial carcinoma compared to FIGO grading in hysterectomy specimens. Int. J. Gynecol. Cancer 21 (2011), 654–660.
27. Winer, I., Ahmed, Q.F., Mert, I., Bandyopadhyay, S., Cote, M., Munkarah, A.R., et al. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?. Int. J. Gynecol. Pathol. 34 (2015), 47–56.
28. Kokka, F., Brockbank, E., Oram, D., Gallagher, C., A., Bryant, Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst. Rev., 2010, CD007926.
29. Martin-Hirsch, P.P., Bryant, A., Keep, S.L., Kitchener, H.C., R., Lilford, Adjuvant progestagens for endometrial cancer. Cochrane Database Syst. Rev., 2011, CD001040.
30. Tamoxifen for early breast cancer: An overview of the randomised trials. Early breast cancer Trialists' collaborative group. Lancet, 351, 1998, 1451–1467.
31. Carlson, M.J., Thiel, K.W., Leslie, K.K., Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int. J. Womens Health 6 (2014), 429–435.
32. Dedes, K.J., Wetterskog, D., Ashworth, A., Kaye, S.B., Reis-Filho, J.S., Emerging therapeutic targets in endometrial cancer. Nat. Rev. Clin. Oncol. 8 (2011), 261–271.
33. Fleming, G.F., Filiaci, V.L., Marzullo, B., Zaino, R.J., Davidson, S.A., Pearl, M., et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol. Oncol. 132 (2014), 585–592.
34. Bonneterre, J., Hutt, E., Bosq, J., Graham, J.D., Powell, M.A., Leblanc, E., et al. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus. Gynecol. Oncol. 138 (2015), 663–667.
35. Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., et al. Integrated genomic characterization of endometrial carcinoma. Nature 497 (2013), 67–73.
36. Stelloo, E., Bosse, T., Nout, R.A., MacKay, H.J., Church, D.N., Nijman, H.W., et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod. Pathol. 28 (2015), 836–844.
37. Nelson, G.S., Pink, A., Lee, S., Han, G., Morris, D., Ogilvie, T., et al. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol. Oncol. 131 (2013), 309–314.
38. Church, D.N., Stelloo, E., Nout, R.A., Valtcheva, N., Depreeuw, J., ter Haar, N., et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J. Natl. Cancer Inst., 107, 2015, dju402.